Sarah Sammons, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared a post on X by Elisabetta Bonzano, Medical Director and Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, adding:
“Pearls for talking to patients:
- AI for 5 years is the goal; more has modest benefits.
- 5 additional years reduces recurrence risk by 3-4%, most of these are new breast events
- reduces distant recurrence by 2% (5 more years)
- no OS benefit.”
Quoting Elisabetta Bonzano’s post about a paper by EBCTCG published in The Lancet:
“Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22,031 postmenopausal women already treated with at least 5 years of endocrine therapy.
- Allocation to 5 further years of AIT reduced subsequent distant recurrence rates by about a quarter
- The absolute further recurrence reduction from 5 further years of AIT appeared greater for women with node-positive than node-negative disease
- 1·2% excess 5-year incidence of reported bone fracture.”
Title: Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22,031 postmenopausal women already treated with at least 5 years of endocrine therapy
Authors: Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
You can read the Full Article on The Lancet.
More posts featuring Sarah Sammons and Elisabetta Bonzano.
